%0 Clinical Trial, Phase II
%T Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
%A Wagner-Johnston ND
%A Schuster SJ
%A deVos S
%A Salles G
%A Jurczak WJ
%A Flowers CR
%A Viardot A
%A Flinn IW
%A Martin P
%A Xing G
%A Rajakumaraswamy N
%A Gopal AK
%J Leuk Lymphoma
%V 62
%N 5
%D 05 2021
%M 33300385
暂无%R 10.1080/10428194.2020.1855344
%X The phase 2 study of idelalisib monotherapy for indolent non-Hodgkin lymphomas (iNHLs) was completed in 2018; final efficacy and safety data with up to 6.7 years long-term follow-up are reported. Patients with iNHL refractory to both rituximab and an alkylating agent were enrolled and received 150 mg idelalisib twice daily (N = 125). Idelalisib resulted in an overall response rate of 57.6% with 34.4% continuing therapy for ≥12 months. The median progression-free survival and duration of response were 11.0 and 11.8 months for follicular lymphoma, 22.2 and 20.4 months for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM), and 6.6 and 18.4 months for marginal zone lymphoma (MZL). Median overall survival after extended follow-up was 48.6 (95% CI 33.9, 71.7) months. Long-term follow-up did not reveal new safety concerns. These data indicate beneficial outcomes with longer follow-up after idelalisib for treatment of iNHL including in patients with LPL/WM and MZL.